The Arrival of Biosimilars
The arrival of biosimilars in the UK, in particular biosimilar rituximab, has created the potential for financial headroom in NHS England.
In this Clinical Science Symposium the EU5 perspective was discussed, clearly highlighting the UK as a beacon of excellence.
Steve Williamson and Hannah Atkins discuss this and talk about the future of bevacizumab; will the launch of a biosimilar bevacizumab improve access to this drug in the UK?
KEYNOTE-042 Discussion, Pembrolizumab Improves Overall Survival Over Chemotherapy in ≥1% PD-L1 Expressing NSCLC
Marcus Warner leads the discussion of what the phase 3 KEYNOTE-042 Study means for advanced/metastatic NSCLC patients in the UK; potentially fewer hospital admissions because treatment related adverse events with chemotherapy can be avoided and the majority of patients being able to start first-line treatment without chemotherapy
However, this does mean that the UK must work harder to ensure the commissioning of services
Late Breaking Abstract 4, KEYNOTE-042 Study
Calum Polwart demonstrates the power of agile video and social media at busy meetings like the ASCO Annual Meeting 2018; with his distinctive flare he brings his initial reaction to the data presented at ASCO to life
What is the Impact of PPIs on the PK and Activity of Sunitinib in GIST Patients?
Hannah Atkins demonstrates why the role of the oncology pharmacist is so important; the concomitant use of PPIs with sunitinib in GIST patients reduces absorption by up to 40% and must therefore be compensated for to avoid impacting progression free survival
Signalling what oncology pharmacists should prepare for or seek further evidence on, this discussion demonstrates how to approach evidence presented at the ASCO Annual Meeting.
For example the Phase I results for ivosidenib in mutant IDH1 relapsed/refractory acute myeloid leukaemia; first IDH1 inhibitor
ASCO Plenary Session: Maintenance Therapy Improves Outcomes in Rhabdomyosarcoma
Discussion of abstract LBA1: Maintenance low dose chemotherapy in patients with high-risk rhabdomyosarcoma (RMS).
RMS is a tumour of mesenchymal origin found mainly in children; it is rare and although the tumour is aggressive, approximately 70-80% of children achieve complete remission with intensive treatment.
However, if patients have a recurrence after initial treatment, most cannot be cured.
This trial was designed around these patients to determine whether maintenance therapy would improve outcomes.
Increases in DFS and OS were reported over standard treatment with the maintenance regimen, demonstrating maintenance therapy improves outcomes in RMS
MMY1001 TRIAL: Phase I Carfilzomib + Daratumumab (DARA) + Dexamethasone
- Trial includes split dose DARA for first dose (days 1 & 2)
- Reduced risk of hospital admission for infusion reaction
- Subsequent capacity impact
Can VEGFA and ICAM1 polymorphisms predict response to bevacizumab?
Apostolos Papachristos' findings (BOPA Bursary Scheme winner) suggest that rs699947, rs5498 and rs2010963 serve as candidate response biomarkers. All three might be able to stratify patients, who may gain a long-term benefit towards the optimization of bevacizumab therapy and achieving better-informed therapeutic outcomes
Biomarker Driven Access to Crizotinib
Crizotinib is a safe and effective treatment option for adults and children with ALK, ROS1, MET alterations
Durability of response to venetoclax (VEN) in patients with CLL relapsed/refractory to ibrutinib and/or idelalisib
Based on longer follow up, VEN monotherapy demonstrates robust activity, with good tolerability in pts with CLL R/R to ibrutinib and/or idelalisib. Though most pts achieved PR, outcomes appear durable with undetectable MRD
Steve Williamson, BOPA Chair, Consultant Cancer Pharmacist
Steve Williamson discusses how the data presented at the ASCO Annual Meeting 2018 will be presented by the BOPA Bursary scheme winners, which will give the UK a distinct insight into ASCO18
ASCO Plenary Session: Some Patients with mRCC Can AVOID Nephrectomy
Discussion of Abstract LBA3: CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in mRCC.
Standard of care has changed in these patients as sunitinib alone was not inferior to cytoreductive nephrectomy followed by sunitinib, which flips the existing paradigm in the management of mRCC
Use of Fosaprepitant in Paediatric Oncology
Should the use of fosaprepitant be a routine alternative for non-compliant paediatric oncology patients on oral aprepitant therapy?
Poster discussion by Joe Williams, BOPA Bursary Scheme
ASCO Plenary Session: TAILOR x
Many women with early breast cancer can avoid chemotherapy.
Endocrine therapy alone was non inferior to ET plus chemotherapy in ER+, HER2-, axillary node-negative eBC with a midrange score as measured by the OncotypeDX breast recurrence score gene expression assay
Three Way Interview Discussing Metastatic Breast Cancer
Reading the data presented at ASCO 2018 is one thing, but diving into that data from an oncology pharmacy perspective is where we can really benefit from the experience in the BOPA Bursary Scheme
Listen to this three way interview at ASCO 2018 to learn more
Neutropenia and Single Agent Pablociclib
Can we [oncology pharmacists] reassure breast cancer patients on single agent pablociclib with neutropenia concerns?
Lack of Cardiac Toxicity in Patients Treated with Aldoxrubicin
Charlie Clark, BOPA Bursary Scheme, discusses the poster presentation of aldoxrubicin with doxorubicin equivalent doses beyond 1000mg/m2
Aldoxrubicin is classical doxorubicin with a linker which binds to albumin on IV administration
Aldoxorubicin lacks cardiotoxicity in these sarcoma patients, although further follow up is required
Highlights of the Breast Cancer Posters at ASCO 2018
One of the advantages of the BOPA Bursary Scheme is having oncology pharmacists at congress who can identify on behalf of their peers the hidden gems at ASCO that benefit the pharmaceutical care of patients in the UK
Is Trastuzumab Monotherapy an Option for Elderly HER2-Positive Patients?
Marcus Warner discusses this poster presented at the ASCO Annual Meeting 2018 [RESPECT Study]; whilst early data, it may indicate that monotherapy trastuzumab is an effective option for elderly patients in the adjuvant HER2-positive breast cancer setting
PERSEPHONE Trial, 6 Versus 12 Months of Adjuvant Herceptin in eBC
Digital discussant with Calum Polwart and Joe Williams dives deeper into this data presented today, Monday 4th June, at the ASCO Annual Meeting 2018
This is an important digital discussant of the clinical implications of 6 versus 12 months trastuzumab treatment in eBC, with recommendations for oncology pharmacy